Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 480
- Registration Number
- NCT05814627
- Locations
- 🇯🇵
Hokkaido Medical Center For Rheumatic Diseases /ID# 270019, Sapporo-shi, Hokkaido, Japan
🇺🇸AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona, United States
🇺🇸Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 255018, Glendale, Arizona, United States
Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse
- Conditions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 49
- Registration Number
- NCT05706038
- Locations
- 🇮🇹
Irccs Ospedale San Raffaele, Milano, Italy
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 207
- Registration Number
- NCT05640245
- Locations
- 🇵🇱
Clinical SIte, Wrocław, Poland
🇪🇸Clinical Site, Sevilla, Spain
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Tianjin Medical University
- Target Recruit Count
- 15
- Registration Number
- NCT05590416
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT05502731
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Yuflyma® (Adalimumab), Patient Experience After Switching
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Celltrion HealthCare France
- Target Recruit Count
- 300
- Registration Number
- NCT05427942
- Locations
- 🇫🇷
Private Practice - ES, Marseille, France
🇫🇷Private practice GB, Toulouse, France
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 87
- Registration Number
- NCT05414201
- Locations
- 🇨🇳
Peking University First Hospital /ID# 243055, Beijing, Beijing, China
🇨🇳Tianjin Medical University Eye Hospital /ID# 243056, Tianjin, China
🇨🇳The second affiliated hospital of Zhejiang University school of medicine /ID# 247251, Hangzhou, Zhejiang, China
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 234
- Registration Number
- NCT05322473
- Locations
- 🇵🇱
Clinical Site, Łódź, Poland
Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Rehab Werida
- Target Recruit Count
- 56
- Registration Number
- NCT05291039
- Locations
- 🇪🇬
Tropical Medicine department, Ain Shams University Hospitals., Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.